[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69919151D1 - Verfahren zur synthese von cox-2 inhibitoren - Google Patents

Verfahren zur synthese von cox-2 inhibitoren

Info

Publication number
DE69919151D1
DE69919151D1 DE69919151T DE69919151T DE69919151D1 DE 69919151 D1 DE69919151 D1 DE 69919151D1 DE 69919151 T DE69919151 T DE 69919151T DE 69919151 T DE69919151 T DE 69919151T DE 69919151 D1 DE69919151 D1 DE 69919151D1
Authority
DE
Germany
Prior art keywords
synthesising
cox
inhibitors
synthesising cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69919151T
Other languages
English (en)
Other versions
DE69919151T2 (de
Inventor
G Corley
W Davies
D Larsen
J Pye
Kai Rossen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69919151D1 publication Critical patent/DE69919151D1/de
Application granted granted Critical
Publication of DE69919151T2 publication Critical patent/DE69919151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69919151T 1998-04-24 1999-04-20 Verfahren zur synthese von cox-2 inhibitoren Expired - Lifetime DE69919151T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US82888P 1998-04-24
US8566898P 1998-05-15 1998-05-15
US85668P 1998-05-15
PCT/US1999/008645 WO1999055830A2 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (2)

Publication Number Publication Date
DE69919151D1 true DE69919151D1 (de) 2004-09-09
DE69919151T2 DE69919151T2 (de) 2005-07-28

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919151T Expired - Lifetime DE69919151T2 (de) 1998-04-24 1999-04-20 Verfahren zur synthese von cox-2 inhibitoren

Country Status (27)

Country Link
US (2) US6040319A (de)
EP (1) EP1071745B1 (de)
JP (2) JP3325264B2 (de)
KR (1) KR100414998B1 (de)
CN (1) CN1178658C (de)
AR (1) AR015279A1 (de)
AT (1) ATE272613T1 (de)
AU (1) AU759469B2 (de)
BR (2) BR9909844B1 (de)
CA (1) CA2329193C (de)
CZ (1) CZ292515B6 (de)
DE (1) DE69919151T2 (de)
DK (1) DK1071745T3 (de)
EA (1) EA002975B1 (de)
ES (1) ES2226378T3 (de)
HR (1) HRP20000722B1 (de)
HU (1) HU227627B1 (de)
IL (2) IL139127A0 (de)
NZ (1) NZ507597A (de)
PL (1) PL193248B1 (de)
PT (1) PT1071745E (de)
RS (1) RS49945B (de)
SI (1) SI1071745T1 (de)
SK (1) SK284805B6 (de)
TW (1) TW474934B (de)
UA (1) UA57143C2 (de)
WO (1) WO1999055830A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP1159270B1 (de) * 1999-01-14 2003-11-05 Lonza AG Verfahren zur herstellung von 1-(6-methylpyridin-3-yl)-2- 4-(methylsulfonyl phenyl)ethanon
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
WO2001037833A1 (en) 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (de) * 2000-07-13 2003-04-09 Pharmacia Corporation Verwendung von cox-2 hemmern zur behandlung und vorbeugung von cox-2-abhängigen augenkrankheiten
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
EP1423114A4 (de) * 2001-05-04 2006-05-17 Merck & Co Inc Verfahren und zusammensetzungen zur behandlung von migräne
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
EP2494992A1 (de) 2004-08-24 2012-09-05 Merck Sharp & Dohme Corp. Kombinationstherapie zur Behandlung von Cyclooxygenase-2-vermittelten Krankheiten oder Zuständen bei Patienten mit Risiko auf thrombotische kardiovaskuläre Ereignisse
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
ES2496465T3 (es) 2009-02-27 2014-09-19 Cadila Healthcare Limited Un procedimiento para la preparación de Etoricoxib
WO2011158250A1 (en) 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
BR112013012008B1 (pt) 2010-11-15 2021-10-13 Virdev Intermediates Pvt. Ltd Processo para o inibidor seletivo da ciclo-oxigenase-2
ITMI20110362A1 (it) 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
EP2831045A2 (de) 2012-03-30 2015-02-04 Mylan Laboratories, Limited Verbessertes verfahren zur herstellung von etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
PL2887924T3 (pl) 2012-08-27 2017-09-29 Cadila Healthcare Limited Kompozycje farmaceutyczne etorykoksybu
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
EP3268085A4 (de) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4-hemmung zur vorbeugung und behandlung von lymphödem beim menschen
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
PT912518E (pt) * 1996-07-18 2003-12-31 Merck Frosst Canada Inc Piridinas substituidas como inibidores selectivos de ciclooxigenase-2
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
HRP20000722B1 (en) 2009-07-31
CA2329193C (en) 2007-01-23
BRPI9917739B8 (pt) 2021-05-25
SI1071745T1 (en) 2004-10-31
PL193248B1 (pl) 2007-01-31
TW474934B (en) 2002-02-01
EP1071745A2 (de) 2001-01-31
CA2329193A1 (en) 1999-11-04
UA57143C2 (uk) 2003-06-16
HUP0101407A2 (hu) 2001-09-28
IL139127A0 (en) 2001-11-25
BR9909844B1 (pt) 2010-10-19
NZ507597A (en) 2004-02-27
EP1071745A4 (de) 2002-05-15
CZ20003940A3 (en) 2001-06-13
YU64100A (sh) 2002-11-15
DK1071745T3 (da) 2004-11-29
KR20010042941A (ko) 2001-05-25
HUP0101407A3 (en) 2002-12-28
ATE272613T1 (de) 2004-08-15
PT1071745E (pt) 2004-11-30
CN1178658C (zh) 2004-12-08
HU227627B1 (en) 2011-10-28
HK1031399A1 (en) 2001-06-15
JP3325264B2 (ja) 2002-09-17
SK15892000A3 (sk) 2001-07-10
JP3834263B2 (ja) 2006-10-18
EP1071745B1 (de) 2004-08-04
CZ292515B6 (cs) 2003-10-15
CN1306425A (zh) 2001-08-01
WO1999055830A3 (en) 1999-12-29
DE69919151T2 (de) 2005-07-28
JP2003040852A (ja) 2003-02-13
BR9909844A (pt) 2001-04-03
US6252116B1 (en) 2001-06-26
AR015279A1 (es) 2001-04-18
HRP20000722A2 (en) 2001-06-30
PL344108A1 (en) 2001-09-24
RS49945B (sr) 2008-09-29
KR100414998B1 (ko) 2004-01-13
AU3655799A (en) 1999-11-16
SK284805B6 (sk) 2005-11-03
JP2002513035A (ja) 2002-05-08
US6040319A (en) 2000-03-21
AU759469B2 (en) 2003-04-17
IL139127A (en) 2006-07-05
ES2226378T3 (es) 2005-03-16
EA200001102A1 (ru) 2001-04-23
EA002975B1 (ru) 2002-12-26
BRPI9917739B1 (pt) 2016-05-03
WO1999055830A2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
DE69919151D1 (de) Verfahren zur synthese von cox-2 inhibitoren
EP1066308A4 (de) Verfahren zur synthese von oligonukleotidedn
DE60027099D1 (de) Verfahren zur Rundfunkausstrahlung von Informationen
ATE388132T1 (de) Verfahren zur hydroformylierung von olefinen
ATE427102T1 (de) Verfahren zur festkírperkristallisierung
DE50003227D1 (de) Verfahren zur verarbeitung von datenstrukturen
DE60043873D1 (de) Verfahren zur Datensicherung
DE69939070D1 (de) Verfahren zur quantifizierung von menschlicher wachsamkeit
DE60103085D1 (de) Verfahren zur verwaltung von resourcen
DE69904754D1 (de) Verfahren zur bioanalyse
DE60037268D1 (de) Verfahren zur durchführung magnetischer chromatographischer assays
DE50013673D1 (de) Verfahren zur Sichtweitenbestimmung
DE60008075D1 (de) Verfahren zur übermittlung von information
DE50010474D1 (de) Verfahren zur verkapselung von bauelementen
EP1216218A4 (de) Verfahren zur anreicherung von kohlenwasserstoffen
DE60012979D1 (de) Verfahren zur selektiven dimerisierung von isobuten
DE69914992D1 (de) Verfahren zur Bereitstellung von Verkehrsinformationen
DE50002724D1 (de) Verfahren zur querstromfiltration
EP1246833A4 (de) Verbessertes verfahren zur synthese von sulfanisierten oligonucleotiden
DE60029182D1 (de) Verfahren zur eindeutigen Abstandsschätzung
DE59900006D1 (de) Verfahren zur Isolierung von gekrümmten Flächen
DE60124884D1 (de) Verfahren zur verbesserung der fotomaskengeometrie
ATE241582T1 (de) Verfahren zur durchführung von aldolkondensationen
EP1160192A4 (de) Verfahren zur mikromanipulation
DE60024535D1 (de) Verfahren zur Zeichentrennung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1071745

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1071745

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213